*****
TODAY’S NEWS
Alpharma/King to pay big fine – American pharmaceutical manufacturer Alpharma Inc. has agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug, Kadian, the Justice Department announced today. The settlement resolves allegations that, between January 1, 2000 and December 29, 2008, Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug, which is used to treat chronic moderate to severe pain. Alpharma is now a wholly-owned subsidiary of Bristol, Tenn.-based King Pharmaceuticals Inc…more
Don’t go buying Lilly drugs on the street corner – In a departure from the recent M.O. of in-transit drug cargo thefts, emboldened thieves hit Eli Lilly’s 70,000-square-foot east coast distribution facility in Enfield, CT. And they hit it hard: $70 million to $75 million worth of Prozac, Cymbalta and Zyprexa–enough to fill a large trailer, according to press reports…more
More and more scripts going unfilled.
Preventing diabetes with drugs – very hard questions being asked.
The interesting background story on new drug Xiaflex (NY Times) – It took half a century. But a tiny drug maker on Long Island has finally found a potentially lucrative use for its only medicine: straightening clenched fingers. And, if research proves successful, treating a condition that causes bent penises…more
RECOMMENDED
Talent Selection/Talent Management – Validated tools and processes to assess employee talent. We’ve got that. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
Salesperson as rebel (Business Week) – but can this mentality even remotely work within pharma?
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
No comments:
Post a Comment